These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1962903)

  • 1. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis.
    Schrader J; Andersson LO; Armstrong VW; Kundt M; Stibbe W; Scheler F
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():41-5. PubMed ID: 1962903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin).
    Persson E
    Acta Med Scand Suppl; 1988; 724():1-56. PubMed ID: 2843005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipolytic and anticoagulant activities of heparin and one of its low molecular weight derivatives].
    Millot F; Bara L; Etienne J; Samama M; Laruelle P
    Nouv Rev Fr Hematol (1978); 1987; 29(6):397-400. PubMed ID: 2837726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of switching unfractionated heparin to low-molecular-weight heparin on serum potassium in hemodialysis patients.
    Ezzatzadegan Jahromi S; Mahmoodi MS; Behroozi F; Roozbeh J; Emamghoreishi F
    Iran J Kidney Dis; 2014 Nov; 8(6):475-80. PubMed ID: 25362223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.
    Schrader J; Stibbe W; Armstrong VW; Kandt M; Muche R; Köstering H; Seidel D; Scheler F
    Kidney Int; 1988 Apr; 33(4):890-6. PubMed ID: 2838681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.
    Borawski J
    Am J Kidney Dis; 2006 Jan; 47(1):37-41. PubMed ID: 16377383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients.
    Schrader J; Stibbe W; Kandt M; Warneke G; Armstrong V; Müller HJ; Scheler F
    ASAIO Trans; 1990; 36(1):28-32. PubMed ID: 2155017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients.
    Kronenberg F; König P; Lhotta K; Steinmetz A; Dieplinger H
    Clin Nephrol; 1995 Jun; 43(6):399-404. PubMed ID: 7554525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of low molecular weight heparin on the hemodialysis model in dogs].
    Hamano S; Sakuragawa N
    Rinsho Byori; 1990 Jul; Suppl 86():165-70. PubMed ID: 2172592
    [No Abstract]   [Full Text] [Related]  

  • 19. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ; Wang L
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.